CRS Weighs Government's Role in Drug R&D, Pricing
By Mari Serebrov
Tuesday, May 1, 2012
WASHINGTON Does the U.S. government's funding of early drug research entitle it to a say in drug pricing discussions? That question is at the center of a debate over whether the current government-academia-industry research model is out of balance.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.